SCHEMBL3881071

SCHEMBL3881071

Brc1cncc(Br)c1.COc1cncc(Br)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PRKACA P17612 1/20 0.43
ROCK1 Q13464 1/20 0.43
DYRK1A Q13627 1/20 0.43
NTRK3 Q16288 1/20 0.43
PKN2 Q16513 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
STK17A Q9UEE5 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7444 0.98
Cyanide SCHEMBL28133661 0.91 CYP1A1 (0.41) CYP1A1CYP1B1ROCK2MAP4K4PRKACA
Formic Acid SCHEMBL28134510 0.86 MKNK2 (0.41) ROCK2MAP4K4PRKACAROCK1DYRK1A
SCHEMBL4441012 0.86 CYP3A4 (0.38) CYP1A1CYP1B1ROCK2MAP4K4PRKACA
SCHEMBL5848746 0.84 CYP1A1 (0.47) CYP1A1CYP1B1CHRNB2CHRNA4
SCHEMBL1557265 0.82 LTA4H (0.45) CYP1A2CYP3A4CYP2C9CYP11B1CYP11B2
SCHEMBL3957255 0.80 CHRNB2 (0.43) CHRNB2CHRNA4
SCHEMBL744752 0.80 CYP1A1 (0.61) CYP1A1CYP1B1ROCK2MAP4K4PRKACA
SCHEMBL7453614 0.78 POLB (0.41) CHRNB2CHRNA4
SCHEMBL2953529 0.78 SMN1; SMN2 (0.49) CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029557-B2 Labeled A4B2 ligands and methods therefor THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-05-12 US disclosed
US-20140050663-A1 Labeled A4B2 Ligands and Methods Therefor THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-02-20 US disclosed
US-8378109-B2 Labeled ALPHA4BETA2 ligands and methods therefor THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-02-19 US disclosed
US-20090297443-A1 Labeled ALPHA4BETA2 Ligands and Methods Therefor THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-12-03 US disclosed
WO-2006086068-A1 LABELED ALPHA-4-BETA-2 LIGANDS AND METHODS THEREFOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140050663-A1 Labeled A4B2 Ligands and Methods Therefor CHRNB1, CHRNB4, CHRNB2 CYP1A1 1573/4885CYP1B1 1004/4885ROCK2 3189/4885
US-20090297443-A1 Labeled ALPHA4BETA2 Ligands and Methods Therefor CHRNE, CHRNB1, CHRNB4 CYP1A1 1623/4885CYP1B1 973/4885ROCK2 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.